Top

Current Reviews in Musculoskeletal Medicine

Published in:

Open Access 01-03-2009

RANK, RANKL and osteoprotegerin in bone biology and disease

Authors: H. L. Wright, H. S. McCarthy, J. Middleton, M. J. Marshall

Published in: Current Reviews in Musculoskeletal Medicine | Issue 1/2009

Abstract

Upon the discovery of RANK, RANKL and OPG in the late 1990s, their importance in the maintenance of the skeletal structure and their dramatic role in bone disease were largely unexpected. In recent years the understanding of these proteins, in particular their regulation, has greatly increased. This review aims to bring the interested reader up to date with the latest news and views on the mechanisms controlling bone resorption in normal and pathological conditions.

Stejskal D, Bartek J, Pastorkova R, Ruzicka V, Oral I, Horalik D. Osteoprotegerin, RANK, RANKL. Biomed Papers. 2001;145:61–4.

Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175–9.PubMedCrossRef

Hofbauer LC, Heufelder AE. Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases. Dtsch Med Wochenschr. 2001;126:145–50.PubMedCrossRef

Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, et al. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab. 2005;90:2964–71.PubMedCrossRef

Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397:315–23.PubMedCrossRef

Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, et al. The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell. 2000;103:41–50.PubMedCrossRef

Kim NS, Kim HJ, Koo BK, Kwon MC, Kim YW, Cho Y, et al. Receptor activator of NF-KappaB ligand regulates the proliferation of mammary epithelial cells via Id2. Mol Cell Biol. 2006;26:1002–13.PubMedCrossRef

Chen G, Sirkar K, Aprikian A, Potti A, Goltzman D, Rabbani S. Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer. 2006;107:289–98.PubMedCrossRef

Hofbauer LC. Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism. Eur J Endocrinol. 1999;141:195–210.PubMedCrossRef

10.

Heijne GV. Life and death of a signal peptide. Nature. 1998;396:111–3.CrossRef

11.

Warren G. Sorting signals and cellular membranes. 2nd ed. 1993. pp. 166–72.

12.

Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–76.PubMedCrossRef

13.

Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE Is a novel ligand of the tumor necrosis factor receptor family that activates C-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272:25190–4.PubMedCrossRef

14.

Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Goto M, et al. A novel molecular mechanism modulating osteoclast differentiation and function. Bone. 1999;25:109–13.PubMedCrossRef

15.

Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004;292:490–5.PubMedCrossRef

16.

Drugarin D, Drugarin M, Negru S, Cioaca R. RANKL-RANK/OPG molecular complex-control factors in bone remodeling. Timisora Med J. 2003;53:297–302.

17.

Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111:1221–30.PubMed

18.

Bord S, Frith E, Ireland DC, Scott MA, Craig JIO, Compston JE. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. Br J Haematol. 2004;126:244–51.PubMedCrossRef

19.

Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-KB ligand and their differential expression in bone and thymus. Endocrinology. 2001;142:1419–26.PubMedCrossRef

20.

Sordillo EM, Pearse RN. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. Cancer. 2003;97:802–12.PubMedCrossRef

21.

Ito S, Hata T. Crystal structure of RANK ligand involved in bone metabolism. Vitam Horm. 2004;67:19–33.PubMedCrossRef

22.

Hikita A, Kadono Y, Chikuda H, Fukuda A, Wakeyama H, Yasuda H, et al. Identification of an alternatively spliced variant of Ca²⁺-promoted Ras inactivator as a possible regulator of RANKL shedding. J Biol Chem. 2005;280:41700–6.PubMedCrossRef

23.

Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309–19.PubMedCrossRef

24.

Woo KM, Choi Y, Ko S-H, Ko JS, Oh K-O, KK Kim. Osteoprotegerin is present on the membrane of osteoclasts isolated from mouse long bones. Exp Mol Med. 2002;34:347–52.PubMed

25.

Kondo T, Kitazawa R, Maeda S, Kitazawa S. 1 Alpha, 25 Dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. J Bone Miner Res. 2004;19:1411–9.PubMedCrossRef

26.

Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, et al. Characterization of structural domains of human osteoclastogenesis inhibitory factor. J Biol Chem. 1998;273:5117–23.PubMedCrossRef

27.

Dehm SM, Bonham K. SRC gene expression in human cancer: the role of transcriptional activation. Biochem Cell Biol. 2004;82:263–74.PubMedCrossRef

28.

Wada T, Nakashima T, Hiroshi N, Penninger JM. RANKL-RANK signaling in osteoclastogenesis and bone disease. TRENDS Mol Med. 2006;12:17–25.PubMedCrossRef

29.

O’Brien EA, Williams JH, Marshall MJ. Osteoprotegerin is produced when prostaglandin synthesis is inhibited causing osteoclasts to detach from the surface of mouse parietal bone and attach to the endocranial membrane. Bone. 2001;28:208–14.PubMedCrossRef

30.

Glass DA, Bialek P, Ahn JD, Starbuck M, Patel MS, Clevers H, et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev Cell. 2005;8:751–64.PubMedCrossRef

31.

Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Donofrio G, Bonomini S, et al. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment. Cancer Res. 2007;67:7665–74.PubMedCrossRef

32.

Hopwood B, Tsykin A, Findlay DM, Fazzalari NL. Microarray gene expression profiling of osteoarthritic bone suggests altered bone remodelling, WNT and transforming growth factor-beta/bone morphogenic protein signalling. Arthritis Res Ther. 2007;9:R100.PubMedCrossRef

33.

Hausler KD, Horwood NJ, Chuman Y, Fisher JL, Ellis J, Martin TJ, et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J Bone Miner Res. 2004;19:1873–81.PubMedCrossRef

34.

Kong YY, Boyle WJ, Penninger JM. Osteoprotegerin ligand: a regulator of immune responses and bone physiology. Immunol Today. 2000;21:495–502.PubMedCrossRef

35.

Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273:14363–7.PubMedCrossRef

36.

Lam J, Nelson CA, Ross FP, Teitelbaum SL, Fremont DH. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J Clin Invest. 2001;108:971–9.PubMed

37.

Gochuico BR, Zhang J, Ma BY, Marshak-Rothstein A, Fine A. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2000;278:1045–51.

38.

Helfrich MH. Osteoclast diseases. Microsc Res Tech. 2003;61:514–32.PubMedCrossRef

39.

Hughes AE, Ralson SH, Marken J, Bell J, MaCPherson H, Wallace RGH, et al. Mutations in the TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24:45–8.PubMedCrossRef

40.

Whyte MP. Paget’s Disease of bone and genetic disorders of RANKL/OPG/RANK/NF-KappaB signalling. Ann N Y Acad Sci. 2006;1068:143–64.PubMedCrossRef

41.

Whyte MP, McAlister WH, Novack DV, Clements KL, Schoenecker PL, Wenkert D. Bisphosphonate-induced osteopetrosis: novel bone modeling defects, metaphyseal osteopenia, and osteosclerosis fractures after drug exposure ceases. J Bone Miner Res. 2008;23:1698–707.PubMedCrossRef

42.

Whyte MP, Huhges AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002;17:26–9.PubMedCrossRef

43.

Sobacchi C, Frattini A, Guerrini MM, Abinun M, Pangrazio A, Susani L, et al. Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL. Nat Genet. 2007;39:960–2.PubMedCrossRef

44.

Cundy T, Hegde M, Naot D, Chong B, King A, Wallace R, et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. Hum Mol Genet. 2002;11:2119–27.PubMedCrossRef

45.

Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and Juvenile Paget’s Disease. N Engl J Med. 2002;347:175–84.PubMedCrossRef

46.

Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337–42.PubMedCrossRef

47.

Chong B, Hegde M, Fawkner M, Seidel J, Tuysuz B, Yuksel B, et al. Mutations in the gene encoding osteoprotegerin cause idiopathic hyperphosphatasia. J Bone Miner Res. 2002;17(suppl 1):S139.

48.

Chong B, Hegde M, Fawkner M, Simonet S, Cassinelli H, Coker M, et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. J Bone Miner Res. 2003;18:2095–104.PubMedCrossRef

49.

Roodman GD. High bone turnover markers predict poor outcome in patients with bone metastasis. J Clin Oncol. 2005;23:4821–2.PubMedCrossRef

50.

Mountzios G, Dimopoulos MA, Bamias A, Papadopoulos G, Kastritis E, Syrigos K, et al. Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumors metastatic to the skeleton. Acta Oncol. 2007;46:221–9.PubMedCrossRef

51.

Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia. 2005;10:169–80.PubMedCrossRef

52.

Klein A, Olendrowitz C, Schmutzler R, Hampl J, Schlag PM, Maass N, Arnold N, Wessel R, Ramser J, Meindl A, Scherneck S, Seitz S. Identification of brain- and bone-specific breast cancer metastasis genes. Cancer Lett. 2008. [Epub ahead of print].

53.

Mundy GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2:584–93.PubMedCrossRef

54.

Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, et al. Osteoprotegerin in prostate cancer bone metastasis. Cancer Res. 2005;65:1710–8.PubMedCrossRef

55.

Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today (Barc). 2002;38:91–102.CrossRef

56.

Yoshino I, Yohena T, Kitajima M, Ushijima C, Nishioka K, Ichinose Y, et al. Survival of non-small cell lung cancer patients with postoperative recurrence at distant organs. Ann Thorac Cardiovasc Surg. 2001;7:204–9.PubMed

57.

Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, et al. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration. J Bone Miner Res. 2006;21:1571–80.PubMedCrossRef

58.

Nakamura ES, Koizumi K, Kobayashi M, Saitoh Y, Arita Y, Nakayama T, et al. RANKL-induced CCL22/macrophage-derived chemokine produced from osteoclasts potentially promotes the bone metastasis of lung cancer expressing its receptor CCR4. Clin Exp Metastasis. 2006;23:9–18.PubMedCrossRef

59.

Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527–33.PubMedCrossRef

60.

Dougall WC, Glaccum M, Charrier K, Kathy R, Brasel K, Smedt T, et al. RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13:2412–24.PubMedCrossRef

61.

Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260–8.PubMedCrossRef

62.

Amizuka N, Shimomura J, Li M, Seki Y, Oda K, Henderson JE, et al. Defective bone remodelling in osteoprotegerin-deficient mice. J Electron Microsc. 2003;52:503–13.CrossRef

63.

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821–31.PubMedCrossRef

64.

Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, et al. Comparison of the effect of denosumab and alendronate on bone mineral density and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2008;24:153–61.CrossRef

65.

Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007;25:4431–7.PubMedCrossRef

66.

Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299–309.PubMedCrossRef

67.

Marathe A, Peterson MC, Mager DE. Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther. 2008;326:555–62.PubMedCrossRef

68.

Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97:887–92.PubMedCrossRef

69.

Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, et al. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther. 2008;16:871–8.PubMedCrossRef

70.

Costa L, Lipton A, Coleman RE. Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther. 2006;3:143–53.PubMedCrossRef

Title: RANK, RANKL and osteoprotegerin in bone biology and disease
Authors: H. L. Wright
H. S. McCarthy
J. Middleton
M. J. Marshall
Publication date: 01-03-2009
Publisher: Humana Press Inc
Published in: Current Reviews in Musculoskeletal Medicine / Issue 1/2009
Electronic ISSN: 1935-9748
DOI: https://doi.org/10.1007/s12178-009-9046-7

At a glance: The STEP trials

Springer Medicine

RANK, RANKL and osteoprotegerin in bone biology and disease

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

The real risks of steroid injection for plantar fasciitis, with a review of conservative therapies

Snowboarding injuries: a review of the literature and an analysis of the potential use of portable ultrasound for mountainside diagnostics

RETRACTED ARTICLE: Osteoid osteoma and osteoblastoma of the spine: a review of the literature

Treatment of bone tumours by radiofrequency thermal ablation

Cervical epidural steroid injections in the management of cervical radiculitis: interlaminar versus transforaminal. A review

Coracoid impingement syndrome: a literature review